Hemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care—A Retrospective Cross-Sectional Study
<span style="text-decoration: underline;">Background:</span> The highly β1-selective beta-blocker Landiolol is known to facilitate efficient and safe rate control in non-compensatory tachycardia or dysrhythmia when administered continuously. However, efficacy and safety data of...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/16/2/134 |
| _version_ | 1797618839117103104 |
|---|---|
| author | Sebastian Schnaubelt Felix Eibensteiner Julia Oppenauer Daniel Tihanyi Marco Neymayer Roman Brock Andrea Kornfehl Christoph Veigl Valentin Al Jalali Sonja Anders Barbara Steinlechner Hans Domanovits Patrick Sulzgruber |
| author_facet | Sebastian Schnaubelt Felix Eibensteiner Julia Oppenauer Daniel Tihanyi Marco Neymayer Roman Brock Andrea Kornfehl Christoph Veigl Valentin Al Jalali Sonja Anders Barbara Steinlechner Hans Domanovits Patrick Sulzgruber |
| author_sort | Sebastian Schnaubelt |
| collection | DOAJ |
| description | <span style="text-decoration: underline;">Background:</span> The highly β1-selective beta-blocker Landiolol is known to facilitate efficient and safe rate control in non-compensatory tachycardia or dysrhythmia when administered continuously. However, efficacy and safety data of the also-available bolus formulation in critically ill patients are scarce. <span style="text-decoration: underline;">Methods:</span> We conducted a retrospective cross-sectional study on a real-life cohort of critical care patients, who had been treated with push-dose Landiolol due to sudden-onset non-compensatory supraventricular tachycardia. Continuous hemodynamic data had been acquired via invasive blood pressure monitoring. <span style="text-decoration: underline;">Results:</span> Thirty patients and 49 bolus applications were analyzed. Successful heart rate control was accomplished in 20 (41%) cases, rhythm control was achieved in 13 (27%) episodes, and 16 (33%) applications showed no effect. Overall, the heart rate was significantly lower (145 (130–150) vs. 105 (100–125) bpm, <i>p</i> < 0.001) in a 90 min post-application observational period in all subgroups. The median changes in blood pressure after the bolus application did not reach clinical significance. Compared with the ventilation settings before the bolus application, the respiratory settings including the required FiO<sub>2</sub> after the bolus application did not differ significantly. No serious adverse events were seen. <span style="text-decoration: underline;">Conclusions:</span> Push-dose Landiolol was safe and effective in critically ill ICU patients. No clinically relevant impact on blood pressure was noted. |
| first_indexed | 2024-03-11T08:18:17Z |
| format | Article |
| id | doaj.art-c2d70d8516d240caac491fe0f9a4f67a |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-11T08:18:17Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-c2d70d8516d240caac491fe0f9a4f67a2023-11-16T22:35:30ZengMDPI AGPharmaceuticals1424-82472023-01-0116213410.3390/ph16020134Hemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care—A Retrospective Cross-Sectional StudySebastian Schnaubelt0Felix Eibensteiner1Julia Oppenauer2Daniel Tihanyi3Marco Neymayer4Roman Brock5Andrea Kornfehl6Christoph Veigl7Valentin Al Jalali8Sonja Anders9Barbara Steinlechner10Hans Domanovits11Patrick Sulzgruber12Department of Emergency Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Emergency Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Emergency Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Pulmonology, Clinic Penzing, Vienna Healthcare Group, 1140 Vienna, AustriaDepartment of Emergency Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Emergency Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Emergency Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Emergency Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Pulmonology, Clinic Penzing, Vienna Healthcare Group, 1140 Vienna, AustriaDepartment of Anaesthesia, Intensive Cate Medicine and Pain Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Emergency Medicine, Medical University of Vienna, 1090 Vienna, AustriaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria<span style="text-decoration: underline;">Background:</span> The highly β1-selective beta-blocker Landiolol is known to facilitate efficient and safe rate control in non-compensatory tachycardia or dysrhythmia when administered continuously. However, efficacy and safety data of the also-available bolus formulation in critically ill patients are scarce. <span style="text-decoration: underline;">Methods:</span> We conducted a retrospective cross-sectional study on a real-life cohort of critical care patients, who had been treated with push-dose Landiolol due to sudden-onset non-compensatory supraventricular tachycardia. Continuous hemodynamic data had been acquired via invasive blood pressure monitoring. <span style="text-decoration: underline;">Results:</span> Thirty patients and 49 bolus applications were analyzed. Successful heart rate control was accomplished in 20 (41%) cases, rhythm control was achieved in 13 (27%) episodes, and 16 (33%) applications showed no effect. Overall, the heart rate was significantly lower (145 (130–150) vs. 105 (100–125) bpm, <i>p</i> < 0.001) in a 90 min post-application observational period in all subgroups. The median changes in blood pressure after the bolus application did not reach clinical significance. Compared with the ventilation settings before the bolus application, the respiratory settings including the required FiO<sub>2</sub> after the bolus application did not differ significantly. No serious adverse events were seen. <span style="text-decoration: underline;">Conclusions:</span> Push-dose Landiolol was safe and effective in critically ill ICU patients. No clinically relevant impact on blood pressure was noted.https://www.mdpi.com/1424-8247/16/2/134Landiololbeta-blockerscritical careintensive carehemodynamic stabilitydysrhythmia |
| spellingShingle | Sebastian Schnaubelt Felix Eibensteiner Julia Oppenauer Daniel Tihanyi Marco Neymayer Roman Brock Andrea Kornfehl Christoph Veigl Valentin Al Jalali Sonja Anders Barbara Steinlechner Hans Domanovits Patrick Sulzgruber Hemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care—A Retrospective Cross-Sectional Study Pharmaceuticals Landiolol beta-blockers critical care intensive care hemodynamic stability dysrhythmia |
| title | Hemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care—A Retrospective Cross-Sectional Study |
| title_full | Hemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care—A Retrospective Cross-Sectional Study |
| title_fullStr | Hemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care—A Retrospective Cross-Sectional Study |
| title_full_unstemmed | Hemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care—A Retrospective Cross-Sectional Study |
| title_short | Hemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care—A Retrospective Cross-Sectional Study |
| title_sort | hemodynamic and rhythmologic effects of push dose landiolol in critical care a retrospective cross sectional study |
| topic | Landiolol beta-blockers critical care intensive care hemodynamic stability dysrhythmia |
| url | https://www.mdpi.com/1424-8247/16/2/134 |
| work_keys_str_mv | AT sebastianschnaubelt hemodynamicandrhythmologiceffectsofpushdoselandiololincriticalcarearetrospectivecrosssectionalstudy AT felixeibensteiner hemodynamicandrhythmologiceffectsofpushdoselandiololincriticalcarearetrospectivecrosssectionalstudy AT juliaoppenauer hemodynamicandrhythmologiceffectsofpushdoselandiololincriticalcarearetrospectivecrosssectionalstudy AT danieltihanyi hemodynamicandrhythmologiceffectsofpushdoselandiololincriticalcarearetrospectivecrosssectionalstudy AT marconeymayer hemodynamicandrhythmologiceffectsofpushdoselandiololincriticalcarearetrospectivecrosssectionalstudy AT romanbrock hemodynamicandrhythmologiceffectsofpushdoselandiololincriticalcarearetrospectivecrosssectionalstudy AT andreakornfehl hemodynamicandrhythmologiceffectsofpushdoselandiololincriticalcarearetrospectivecrosssectionalstudy AT christophveigl hemodynamicandrhythmologiceffectsofpushdoselandiololincriticalcarearetrospectivecrosssectionalstudy AT valentinaljalali hemodynamicandrhythmologiceffectsofpushdoselandiololincriticalcarearetrospectivecrosssectionalstudy AT sonjaanders hemodynamicandrhythmologiceffectsofpushdoselandiololincriticalcarearetrospectivecrosssectionalstudy AT barbarasteinlechner hemodynamicandrhythmologiceffectsofpushdoselandiololincriticalcarearetrospectivecrosssectionalstudy AT hansdomanovits hemodynamicandrhythmologiceffectsofpushdoselandiololincriticalcarearetrospectivecrosssectionalstudy AT patricksulzgruber hemodynamicandrhythmologiceffectsofpushdoselandiololincriticalcarearetrospectivecrosssectionalstudy |